Indy without Lilly, the 500?
An Indiana University prof thinks Indianapolis should anticipate a future without Indianapolis Motor Speedway, and a potentially
reduced Eli Lilly and Co.
Life Science & Biotech
Articles
Health firms still attracting venture capital
The uncertainty of health care reform and a bad economy curtailed venture capital flow in 2009. That trend hit Indianapolis,
but the rest of the state actually saw an increase.
Dow AgroSciences profit falls despite revenue increase
Indianapolis-based Dow AgroSciences said Tuesday it posted a profit of $69 million in the fourth quarter, down 19 percent
from the prior year because of increased research and development spending and higher administrative expenses. Revenue was
up 17 percent.
City of Greenwood might fund launch of insulin maker
Greenwood-based Zimmerman Biotechnologies LLC hopes to become the first company in the United States to make generic insulin,
a long-awaited development in diabetes treatment. The Greenwood Common Council on Feb. 1 will consider an $8.4 million deal
that would finance construction of an insulin factory, as well as help Zimmerman with FDA-approval and equipment expenses.
TechPoint accepting nominations for Mira technology awards
The awards are meant to showcase Indiana’s high-tech success stories and raise the profile of the tech community.
Dow Agro in legal skirmish over canola oil
Indianapolis-based Dow AgroSciences LLC has sued Cooper Industries Plc in an effort to clarify its rights to make a canola-based
fluid used in electrical transformers.
Entrepreneur says quality of venture capital as important as quantity
Jim Pearson knows a thing or two about raising money from venture capitalists. And he has some advice for BioCrossroads:
Teach entrepreneurs the value of money.
First Indiana Future Fund off to a slow start
More than half of the venture capital fund’s original investors took a pass on its $58 million successor, the newly launched
INext.
Senate rejects drug-importation proposal
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers
such as Indianapolis-based Eli Lilly and Co. a victory.
New BioCrossroads venture fund raises $58 million
The new INext fund is the successor to the $73 million Indiana Future Fund, which the life science initiative raised in 2003.
Company’s medical device earns expedited review
FAST Diagnostics LLC said initial human trials on its method to measure kidney function faster and more accurately than existing
techniques could begin as early as next year, with commercialization following by 2012.
Ariad asks court to restore patent-suit win against Lilly
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.
Builder looks to cold storage for steady work in a weak economy
Cold storage might become a hot business for a building contractor.
Downtown life sciences corridor flagged for development
A new task force is charged with making recommendations for development of the city’s downtown certified technology
park.
Zimmer offering seeks $1B
The Indiana-based orthopedic implant maker plans to use the proceeds to pay down debt and for general corporate purposes.
Aarden Pharmaceuticals chose Indianapolis over San Diego for headquarters
Thanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided
locating here would give Aarden a better chance of success.
FDA questions role of payments in Zimmer study
Federal health officials say an implant from Indiana-based Zimmer Holdings Inc. appears to be effective in treating spinal
problems, but questions remain about whether company payments to doctors influenced the device’s trial data.
Indiana among 15 states accusing Amgen of illegal kickbacks
Biotechnology behemoth Amgen Inc. is being sued by 15 states, including Indiana, alleging the company gave kickbacks to medical
providers to help boost sales of the Aranesp.
Lilly opens new biotech center in San Diego
Lilly is opening the San Diego biotech center a year after launching a biotech R&D center in Indianapolis.
Pace of life sciences venture capital deals in Indiana picks up
After no Indiana health and life sciences firms announced venture capital deals in the second quarter, five did so in the
third, and two more have already this month.